10429_infocus_parkinson_bw_17_tot

16. Aarsland D, Larsen JP, Goek Lim N, et al. Range of neuropsychiatric disturbances inpatients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;67:492-6.17. Thanvi BR, Munshi SK, Vijaykumar N, Lo TC. Neuropsychiatric nonmotor aspectsof Parkinson’s disease. Postgrad Med J. 2003;79:561-5.18. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patientswith Parkinson’s disease? J Neurol Neurosurg Psychiatry. 2000;69:308-12.19. Aarsland D, Andersen K, Larsen JP, et al. Prevalence and characteristics of dementiain Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60:387-92.20. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies ofdepression in Parkinson’s disease. Mov Disord. 2008;23:183-9.21. Remy P, Doder M, Lees A, et al. Depression in Parkinson’s disease: loss of dopamineand noradrenaline innervation in the limbic system. Brain. 2005;128:1314-22.22. Doder M, Rabiner EA, Turjanski N, et al. Brain serotonin 5HT1A receptors inParkinson’s disease with and without depression measured by positron emissiontomography with 11C-WAY 10635. Mov Disord. 2000;15:213.23. Lauterbach EC, Freeman A, Vogel RL. Differential DSM-III psychiatric disorderprevalence profiles in dystonia and Parkinson’s disease. J Neuropsychiatry ClinNeurosci. 2004;16:29-36.24. Nilsson FM, Kessig LV, Bolwig TG. Increased risk of developing Parkinson’s diseasefor patients with major affective disorders. Acta Psychiatr Scand. 2001;104:380-6.25. Schurmann AG, van den Akker H, Ensinck KTJL, et al. Increased risk of Parkinson’sdisease after depression: a retrospective cohort study. Neurology. 2002;58:1501-4.26. Myslobodsky M, Lalonde FM, Hicks L. Are patients with Parkinson’s diseasesuicidal? J Geriatr Psychiatry Neurol. 2001;14:120-4.27. Funkiewiez A, Ardouin C, Caputo E, et al. Long term effects of bilateral subthalamicnucleus stimulation on cognitive function, mood, and behaviour in Parkinson’sdisease. J Neurol Neurosurg Psychiatry. 2004;75:834-9.28. Weintraub D, Moberg PJ, Duda JE, et al. Effect of psychiatric and other nonmotorsymptoms on disability in Parkinson’s disease. J Am Geriatr Soc. 2004;52:784-8.29. Weisskopf MG, Chen H, Schwarzschild MA, et al. Prospective study of phobicanxiety and risk of Parkinson’s disease. Mov Disord. 2003;18:646-51.30. Shiba M, Bower JH, Maraganore DM, et al. Anxiety disorders and depressivedisorders preceding Parkinson’s disease: a case-control study. Mov Disord.2000;15:669-77.31. Singh A, Althoff R, Martineau J, Jacobson J. Pramipexole, ropinirole, and mania inParkinson’s disease. Am J Psychiatry. 2005;162:814-5.32. Pluck GC, Brown RG. Apathy in Parkinson’s disease. J Neurol Neurosurg Psychiatry.2002;73:636-42.33. Alves G, Wentzel-Larsen T, Larsen JP. Is fatigue an independent and persistentsymptom in patients with Parkinson disease? Neurology. 2004;63:1908-11.34. Brown RG, Pluck G. Negative symptoms: the ‘pathology’ of motivation and goaldirectedbehaviour. Trends Neurosci. 2000;23:412-7.76 InFocus Niet-motorische verschijnselen bij de ziekte van Parkinson